Goldman Sachs Group Inc Bridge Bio Pharma, Inc. Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
A detailed history of Goldman Sachs Group Inc transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 2,051,973 shares of BBIO stock, worth $47.3 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,051,973
Previous 2,298,039
10.71%
Holding current value
$47.3 Million
Previous $58.2 Million
10.25%
% of portfolio
0.01%
Previous 0.01%
Shares
19 transactions
Others Institutions Holding BBIO
# of Institutions
291Shares Held
171MCall Options Held
10.4MPut Options Held
2.37M-
Kohlberg Kravis Roberts & Co. L.P. New York, NY25.3MShares$582 Million35.94% of portfolio
-
Viking Global Investors LP25.1MShares$579 Million2.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.2MShares$327 Million0.01% of portfolio
-
Black Rock Inc. New York, NY12.4MShares$287 Million0.01% of portfolio
-
Aisling Capital Management LP New York, NY6.07MShares$140 Million63.58% of portfolio
About BridgeBio Pharma, Inc.
- Ticker BBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 148,246,000
- Market Cap $3.42B
- Description
- BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...